Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — FY2021 Earnings Presentation
21 slides from Abcellera Biologics's earnings presentation, Feb 24, 2022
Slide 1: Full Year 2021 Business Update
ellera FULL YEAR 2021 BUSINESS UPDATE FEB 24, 2022
Slide 2: Disclaimer
FULL YEAR 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA ny DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's
Slide 3: Creating & Capturing Value: Business Update Summary
CREATING & CAPTURING VALUE FULL YEAR 2021. BUSINESS UPDATE SUMMARY. ee NEW programs under contract 26 NEW programs started 4 MOLECULES entered clinical testing 156 cumulative programs under contract 718 cumulative programs started >$720M in cash, cash equivalents & marketable securities
Slide 4: Proven Technology Leader in Antibody Discovery
FULL YEAR 2021 BUSINESS UPDATE PROVEN TECHNOLOGY LEADER IN ANTIBODY DISCOVERY. S 0 U re e from a single source search 2°. . afew . ENZINCEL serrsesese . a panel of deliver cer
Slide 5: Portfolio Diversified Across Modalities, Partner Size, Deal Type
FULL YEAR 2021 BUSINESS UPDATE PORTFOLIO DIVERSIFIED ACROSS MODALITIES, PARTNER SIZE, DEAL TYPE. moderna multi-target multi-year Gg GILEAD undisclosed QEQG: multi-target multi-year multi-target multi-year @ angios oncology, immunology undisclosed a multi-target + additional indications multi-year DY
Slide 6: Large Diversified Portfolio in Next-Gen Antibody Therapies
FULL YEAR 2021 BUSINESS UPDATE LARGE DIVERSIFIED 5Q% ovosioss p 0 RTFO LI 0 17” neurology IN NEXT-GEN Ba — ANTIBODY So: — 3% dermatology THERAPIES. — ie 50” human health, ' known Portfolio of 131 programs 2 Q% \ : n=65 | with downstream participation , 7 A 4 on human health, is diversified across th
Slide 7: Illustrative Revenue Profile for One Successful Partnered Program
ILLUSTRATIVE REVENUE PROFILE FOR ONE SUCCESSFUL PARTNERED PROGRAM. AbCellera participation in programs is strongly weighted towards downstream success. ee aggregate of approval & commercial milestones clinical milestones research fees = | w a <= =) a S na %) uw z a = cy a a o Nn = <= wi > = =i =) ri
Slide 8: COVID-19 Antibody Program
COVID-19 ANTIBODY PROGRAM. Similar revenue structure to typical program realized on a compressed timeline. royalties in aggregate of (to Dec 31, 2021), over 95% of total program revenue w a <= =) a S na %) uw z a = oa a a o Nn = < wi > = =i =) ri approval & commercial milestones clinical milestones
Slide 9: Focussed on Key Value Drivers
FULL YEAR 2021 BUSINESS UPDATE FOCUSSED ON KEY VALUE DRIVERS. a Probability of Success Increase the probability of clinical and commercial success by identifying antibodies with superior biophysical properties. Speed Increase diversity at the start of discovery to maximize the likelihood that suitab
Slide 10: Strong Growth of Royalty Rates
w = <= =) a S na %) uw z a = cy a nu o N C4 <= wi > — a =) in STRONG GROWTH OF ROYALTY RATES. Deepening stakes evidenced by increasing royalty rates. — 5th / 95" percentile * programs under i interquartile range oi a downstream O mean participation signed in period shown Royalty on Net Sales Include
Slide 11: Flexible Deal Structures to Capture Value
w a <= =) a S na %) uw z a = oa a a o Nn = < wi > = =i =) ri FLEXIBLE DEAL STRUCTURES TO CAPTURE VALUE. Milestone Payments (USD) all Programs Under Contract (not probability adjusted) preclinical $0.05B | In addition to royalties and + milestones, some deal structures include equity/equity-like posi
Slide 12: Bebtelovimab Is the Most Potent Antibody Against Omicron
BEBTELOVIMAB IS THE MOST POTENT ANTIBODY IN DEVELOPMENT AGAINST THE OMICRON VARIANT. >10 10+ 5.8495 e 2.0373 e ' ° >1000x 0.2814 0.3 | oer | less potent* 0.2689 e L >400x _| e less potent* _ >50x | less potent* w = <= =) a S na %) uw z a = cy a nu o N C4 <= wi > — a =) in #8 3s RE *against Omicron,
Slide 13: Advancing GPCRs, Ion Channels & Bispecific Antibodies
FULL YEAR 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA ADVANCING GPCRs, ION CHANNELS”. _— & BISPECIFIC iy Vgee a ANTIBODIES. } antibodies BAe fee entibodies= — OrthoMab i Bispecific Platform Acquired in 2020 ae GPCRs & ION CHANNELS TRIANNI Recent acquisitions Acquired in 2020 successfully integrated i
Slide 14: 2021
2021
Slide 15: Strong portfolio growth
Strong portfolio growth. Cumulative # of Cumulative # of Program Starts Molecules in the Clinic my = S a 2 78 5 ” a 80 5 = 70 s Total # of 4 a 60 a Programs Under Contract 156° 50 = 3 [-4 40 =x Ks Total # of 30 7 a 36 Py 5 Discovery Partners 1 10 | 3 2015 2016 2017 2018 2019 2020 2021 2015 2016 2017
Slide 16: Molecules in the clinic
w = <= =) a S na %) uw z a = cy a nu o N C4 <= wi > — a =) in 5 molecules in the clinic, 2 authorized for emergency use. MOLECULE STAGE PARTNER THERAPEUTIC AREA PROGRAM TYPE bamlanivimab (LY-CoV555) bebtelovimab (LY-Cov1404) NBL-012 NBL-015 IVX-01 Marketed, Emergency Use Authorization (EUA) Marketed
Slide 17: $375.2M total revenue, driven by royalties & milestone payments
$375.2M total revenue, driven by royalties & milestone payments for bamlanivimab. Revenue USD $375.2M m ROYALTIES O MILESTONES LICENSING M@ RESEARCH FEES $233.2M w a <x ra) a S na %) uw z a = oa a a o Nn = < wi > = =i =) ri 2020 2021
Slide 18: Operating expenses reflect strengthening of the platform
Operating expenses reflect strengthening of the platform. Operating Expenses USD RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN w = <= =) a S na %) uw z a = cy a nu o N C4 <= wi > — a =) in 2020 2021 2020 2021 2020 2021
Slide 19: Net earnings of $153.5M
w = <= =) a S na %) uw z a = cy a nu o N C4 <= wi > — a =) in Net earnings of $153.5M: equivalent to $0.56 (basic) and $0.48 (ditutea) per share. Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC EARNINGS PER SHARE: DILUTED $153.5M $118.9M $0.53 $0.56 $0.45 $0.48 2020 2021 2020 2021 2020 2021
Slide 20: Over $720 million in total cash, equivalents, and marketable securities
w a <= =) a S na %) uw z a = cy a a o N C4 <= wi > — a =) in Over $720 million in total cash, equivalents, and marketable securities. Cash Flows USD $748M $247M Marketable Securities $247M $594M Marketable Securities $58M PPGE ($332M) (S4M) $476M Cash & Equivalents 2020 Y/E OPERATING INVESTING FINAN
Slide 21: FULL YEAR 2021 BUSINESS UPDATE
FULL YEAR 2021 BUSINESS UPDATE